1. Home
  2. Companies
  3. Emerald BioVentures
EB

Emerald BioVentures

About

Emerald Bioventures was formed to incubate and build transformational life sciences companies with extraordinary entrepreneurs. Based on cutting-edge science, medicine, and technology, our aim is to improve human health today and for future generations.

Emerald is one of at least several dozen life sciences focused incubators based in the United States. ​

A unique aspect of our philosophy is the combination of a mission-driven approach with a focus on “white space” problems.​

That is, we take on hard problems that, if solved, have the potential to positively impact humanity. ​

We will often start with a blank sheet of paper and look at a difficult medical issue like autism, breast cancer, heart failure or the obesity epidemic and we ask “how can one best address these diseases?” ​

We then go about creating a for-profit business that will permit this to happen. In other cases, we will encounter a new technology or scientific innovation and then go through an ideation phase of figuring out how to use the innovation for the benefit of patients. ​

A key aspect of Emerald’s philosophy is that mission-driven businesses need to ultimately become profitable. Otherwise, they will not be able to deliver on their mission.

Similar companies

TI

Trinity Innovation Bioventure Singapore

Trinity Innovation Bioventure Singapore is a licensed biomed venture capital fund focusing on innovation and value investment with deep insight and experience on Asia markets. We are part of the Trinity Innovation Fund group, founded in 2018, managing multiple VC funds in the region. We are an experienced team led by industrial veterans who have managed multiple VC funds and invested over dozens of biotech companies. Our StrengthAccess to China market through synergy with TIF: Two organizations, One Team Multi-dimensional value-added post investment to enhance possibility of success and returns Clear investment thesis: In Asia, for Global; Leverage regional synergy and realize future value Best-in-class team in biomed investment with strong track record Our Focus TIBS seeks to invest and build great companies that emerging biotechnology leads to innovative therapeutics to address global unmet medical needs. We focus on incubating and growing potential early-stage biotech start-ups with breakthrough platform technology, differentiated scientific merit and commercial value. Our Core CompetencyValue Discovery: Select investment projects based on precise judgements from in-depth research Project Incubation: Incubate cutting-edge science or outstanding entrepreneurs with innovative approaches. Unique incubation strategy: project management by investment team to increase the asset value; management team recruitment to maximize the equity value and capital efficiency Help entrepreneurs to grow rapidly with proprietary foresight, industry understanding and resources

CB

Cambrian Biopharma

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

IB

InnoCom Bio Equities

InnoCom makes investments into worthy Life Science companies, providing: Investment opportunities in cutting edge technologies Access to early commercialization for life Science innovators Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing Industry networking to access revenue at 2-3 years following pre-clinical trials Providing revenue and/or takeout at 7 years end of clinical trials Business Counsel and advice to the company management team Corporate Officer participation, setting up strong Systems, Procedures, and Protocols Board of Directors Membership, building strong Corporate Governance Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years Enhancing the delivery of health solutions to the patients who need them

KH

K2 HealthVentures

K2HV’s investment professionals bring together substantial experience across multiple verticals in healthcare finance and operations, as well as considerable scientific knowledge. Our diverse backgrounds and experience give us a deep understanding of the needs of innovative healthcare companies throughout their lifecycles, and underpin our innovative and creative approach to investing. Our leadership team has committed more than $4 billion to over 100 private and public companies in the life sciences and healthcare industries. High Impact Investments, Long-Term ViewUniquely flexible, permanent capital structure enables us to provide long-term financing solutions and meet the evolving capital needs of growing companies Broad investment mandate allows us to be creative with financing structures Primary focus on customized debt financings, but able to invest in equity as well

SV

Synapto Ventures

Empowering life science innovators to reach their full potential by providing strategic financial guidance and unlocking global investment opportunities. Your Strategic Partner for Fundraising in Life Sciences Our proven track record makes us your trusted partner for your fundraising journey 2 exits in 2024 through Gold Nest Capital - Group's asset management company USD 50 M raised in 2024 for life science companies 151 company due diligences since 2020 as investment opportunities/services 100% client satisfaction for three years running 75% requests to renew for three years running 1 biomanufacturing company founded in 2023

AV

Atlas Venture

We build breakthrough biotechnology companies. Exceptional entrepreneurs and scientists translate innovation into novel medicines. We play the long game with urgency. Patience, discipline, and vision to bring new transformational medicines to life. We are relentless truth-seekers. Our seed-led investment model uncovers the most promising opportunities. We understand the power of community. We prioritize a collaborative, science-first, patient-centric culture.